Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention.

AIMS Several studies have demonstrated that the mutant *2 allele of the CYP2C19 681G>A loss-of-function polymorphism is associated with diminished metabolization of clopidogrel into its active thiol metabolite and an attenuated platelet response to clopidogrel treatment. It is not known whether patients carrying the mutant CYP2C19*2 allele have a higher risk of stent thrombosis (ST) compared with homozygous CYP2C19*1 wild-type allele carriers following percutaneous coronary intervention (PCI). The aim of this study was to assess the impact of the CYP2C19 681G>A loss-of-function polymorphism on ST following PCI performed after pre-treatment with clopidogrel. METHODS AND RESULTS The study population included 2485 consecutive patients undergoing coronary stent placement after pre-treatment with 600 mg of clopidogrel. Genotypes were determined with a TaqMan assay. The primary endpoint of the study was the incidence of definite ST within 30 days following PCI. Of the patients studied, 1805 (73%) were CYP2C19 wild-type homozygotes (*1/*1) and 680 (27%) carried at least one *2 allele (*1/*2 or *2/*2). The cumulative 30-day incidence of ST was significantly higher in CYP2C19*2 allele carriers (*1/*2 or *2/*2) vs. CYP2C19 wild-type homozygotes (*1/*1) [10 patients (1.5%) in CYP2C19*2 allele carriers vs. 7 (0.4%) in CYP2C19 wild-type homozygotes (*1/*1), HR 3.81, 95% CI 1.45-10.02, P = 0.007; P = 0.006 after adjustment for confounding variables]. The risk of ST was highest (2.1%) in patients with the CYP2C19 *2/*2 genotype (P = 0.002). CONCLUSION CYP2C19*2 carrier status is significantly associated with an increased risk of ST following coronary stent placement.

[1]  M. Zwahlen,et al.  Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. , 2008, Journal of the American College of Cardiology.

[2]  T. Furuta,et al.  The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects , 2008, Journal of thrombosis and haemostasis : JTH.

[3]  A. Kastrati,et al.  Pharmacokinetics of clopidogrel in patients with stent thrombosis , 2008, Journal of thrombosis and haemostasis : JTH.

[4]  M. Fromm,et al.  Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. , 2008, Journal of the American College of Cardiology.

[5]  P. Morange,et al.  Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. , 2008, The American journal of cardiology.

[6]  Matthew J Price,et al.  Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. , 2008, European heart journal.

[7]  B. Giusti,et al.  Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients , 2007, Pharmacogenetics and genomics.

[8]  S. Iturria,et al.  Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel , 2007, Journal of thrombosis and haemostasis : JTH.

[9]  Simon Wandel,et al.  Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis , 2007, The Lancet.

[10]  P. Auquier,et al.  Vasodilator‐stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events , 2007, Journal of thrombosis and haemostasis : JTH.

[11]  A. Gori,et al.  Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. , 2007, Journal of the American College of Cardiology.

[12]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[13]  C. Macaya,et al.  Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. , 2007, Journal of the American College of Cardiology.

[14]  F. Neumann,et al.  Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. , 2006, Journal of the American College of Cardiology.

[15]  A. Bura,et al.  Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. , 2006, Blood.

[16]  E. Trabetti,et al.  Contribution of Gene Sequence Variations of the Hepatic Cytochrome P450 3A4 Enzyme to Variability in Individual Responsiveness to Clopidogrel , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[17]  A. Kastrati,et al.  Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. , 2006, JAMA.

[18]  Lippincott Williams Wilkins,et al.  ACC/AHA/SCAI Practice Guidelines, February 21, 2006 , 2006 .

[19]  J. Ornato,et al.  ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). , 2006, Circulation.

[20]  Joseph P Ornato,et al.  ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). , 2006, Journal of the American College of Cardiology.

[21]  A. Wieczorek,et al.  A patient with stent thrombosis, clopidogrel-resistance and failure to metabolize clopidogrel to its active metabolite , 2005, Thrombosis and Haemostasis.

[22]  P. Serruys,et al.  Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. , 2005, Journal of the American College of Cardiology.

[23]  Deepak L. Bhatt,et al.  Variability in platelet responsiveness to clopidogrel among 544 individuals. , 2005, Journal of the American College of Cardiology.

[24]  O. Hess,et al.  Stent thrombosis is associated with an impaired response to antiplatelet therapy. , 2005, Journal of the American College of Cardiology.

[25]  A. Kastrati,et al.  Randomized Clinical Trial of Abciximab in Diabetic Patients Undergoing Elective Percutaneous Coronary Interventions After Treatment With a High Loading Dose of Clopidogrel , 2004, Circulation.

[26]  J. Hausleiter,et al.  A randomized trial comparing phosphorylcholine‐coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries , 2004, Journal of internal medicine.

[27]  P. Watkins,et al.  Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel Resistance , 2004, Circulation.

[28]  A. Kastrati,et al.  A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. , 2004, The New England journal of medicine.

[29]  J. Goldstein,et al.  Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. , 2001, British journal of clinical pharmacology.

[30]  F. Neumann,et al.  Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting. , 2001, Journal of the American College of Cardiology.

[31]  David Julius,et al.  Identification of the platelet ADP receptor targeted by antithrombotic drugs , 2001, Nature.

[32]  J. Herbert,et al.  Identification and Biological Activity of the Active Metabolite of Clopidogrel , 2000, Thrombosis and Haemostasis.

[33]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .